Abstract
An experimental model of tumor dormancy therapy for advanced head and neck carcinoma was developed. After transplantation of KB cells into nude mice, the mice were given tiracoxib, a selective cyclooxygenase (COX)‐2 inhibitor, probucol, an antioxidant, and S‐1, an oral pro‐drug of 5‐fluorouracil (5‐FU), or combinations of two of them. The combined administration of tiracoxib with probucol significantly inhibited the tumor growth. The angiogenesis in this group was markedly reduced. Tiracoxib and probucol did not affect the intratumoral concentration of 5‐FU when coadministered with S‐1. The combined use of tiracoxib and probucol is thus a candidate for use in maintenance therapy after the primary therapy for patients with advanced head and neck carcinoma.
Keywords: COX‐2 inhibitor, Antioxidant, S‐1, Tumor dormancy, Head and neck carcinoma
Full Text
The Full Text of this article is available as a PDF (65.0 KB).
REFERENCES
- 1. ) Nishimura , G. , Yanoma , S. , Mizuno , H. , Kawakami , K. and Tsukuda , M.A selective cyclooxygenase‐2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells . Jpn. J. Cancer Res. , 90 , 1152 – 1162 ( 1999. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. ) Nishimura , G. , Yanoma , S. , Mizuno , H. , Kawakami , K. and Tsukuda , M.An antioxidant, probucol, induces anti‐angiogenesis and apoptosis in athymic nude mouse xenografted human head and neck squamous carcinoma cells . Jpn. J. Cancer Res. , 90 , 1224 – 1230 ( 1999. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. ) Nishimura , G. , Yanoma , S. , Mizuno , H. , Taguchi , T. , Ikeda , Y. and Tsukuda , M.Therapeutic effect of 1 M tegafur‐0.4 M 5‐chloro‐2,4‐dihydroxypyridine‐1 M potassium oxonate (S‐1) on head and neck squamous carcinoma cells . Cancer Lett. ( 2000. ), in press . [DOI] [PubMed]
- 4. ) Eagle , H.Propagation in a fluid medium of a human epidermoid carcinoma, strain KB . Proc. Soc. Exp. Biol. Med. , 89 , 362 – 364 ( 1955. ). [DOI] [PubMed] [Google Scholar]
- 5. ) Ku , G. , Doherty , N. S. , Wolos , J. A. and Jackson , L. R.Inhibition by probucol of interleukin 1 secretion and its implication in atherosclerosis . Am. J. Cardiol. , 62 , 77B – 81B ( 1988. ). [DOI] [PubMed] [Google Scholar]
- 6. ) Cushing , S. D. , Berliner , J. A. , Valente , A. J. , Territo , M. C. , Navab , M. , Parhami , F. , Gerrity , R. , Schwartz , C. J. and Fogelman , A. M.Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells . Proc. Natl. Acad. Sci. USA , 87 , 5134 – 5138 ( 1990. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. ) Stiko‐Rahm , A. , Hultgardh‐Nilsson , A. , Regnstrom , J. , Hamsten , A. and Nilsson , J.Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells . Arterioscler. Thromb. , 12 , 1099 – 1109 ( 1992. ). [DOI] [PubMed] [Google Scholar]
- 8. ) Shirasaka , T. , Shimamoto , Y. , Ohshimo , H. , Yamaguchi , M. , Kato , T. , Yonekura , K. and Fukushima , M.Development of a novel form of 5‐fluorouracil derivative (S‐1) directed to the potentiation of the tumor‐selective cytotoxicity of 5‐fluorouracil by two biochemical modulators . Anticancer Drugs , 7 , 548 – 557 ( 1996. ). [DOI] [PubMed] [Google Scholar]
- 9. ) Tatsumi , K. , Fukushima , M. , Shirasaka , T. and Fujii , S.Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5‐fluorouracil degradation in rat liver extracts . Jpn. J. Cancer Res. ( Gann ), 78 , 748 – 755 ( 1987. ). [PubMed] [Google Scholar]
- 10. ) Shirasaka , T. , Shimamoto , Y. and Fukushima , M.Inhibition of oxonic acid on gastrointestinal toxicity of 5‐fluorouracil without loss of its antitumor activity in rats . Cancer Res. , 53 , 4004 – 4009 ( 1993. ). [PubMed] [Google Scholar]